Category: Partners

SAN DIEGO, CA / ACCESS Newswire / September 11, 2025 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company focused on rebalancing inflammation, announced today the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 4,355,000 shares of common stock, issued by the Company on May 29, 2025 (the “Existing Warrants”), at the existing exercise price of $2.20 per share. The shares of common stock issuable upon exercise of the Existing Warrants are registered pursuant to an effective registration statement on Form S-1 (File No. 333-287423). The closing of the offering is expected to occur on or about September 11, 2025, subject to satisfaction of customary closing conditions.

Roth Capital Partners is acting as the Company’s financial advisor for this transaction.

In consideration for the immediate exercise of the warrants for cash, the exercising holders will receive new Class I warrants to purchase shares of common stock in a private placement pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (the “1933 Act”). The new Class I warrants will be exercisable into an aggregate of up to 13,065,000 shares of common stock, will be exercisable beginning on the effective date of stockholder approval of the shares issuable upon exercise of the new warrants at an exercise price of $2.20 per share, and have a term of exercise equal to five years after the stockholder approval date. The securities offered in the private placement have not been registered under the Securities Act of 1933, as amended, or applicable under state securities laws. Accordingly, the securities may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. As part of the transaction, the Company has agreed to file a resale registration statement on Form S-3 with the Securities and Exchange Commission within 20 days of the closing to register the resale of the shares of common stock underlying the new Class I warrants issued in the private placement.

This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

About Revelation Biosciences, Inc.

Revelation Biosciences, Inc. is a clinical stage life sciences company focused on rebalancing inflammation using its proprietary formulation Gemini. Revelation has multiple ongoing programs to evaluate Gemini, including as a prevention for post-surgical infection, as prevention for acute kidney injury and for the treatment of chronic kidney disease.

For more information, please visit www.RevBiosciences.com.

Forward-Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These forward-looking statements are generally identified by the words “anticipate”, “believe”, “expect”, “estimate”, “plan”, “outlook”, and “project” and other similar expressions. We caution investors that forward-looking statements are based on management’s expectations and are only predictions or statements of current expectations and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from those anticipated by the forward-looking statements. Revelation cautions readers not to place undue reliance on any such forward looking statements, which speak only as of the date they were made. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: the ability of Revelation to meet its financial and strategic goals, due to, among other things, competition; the ability of Revelation to grow and manage growth profitability and retain its key employees; the possibility that the Revelation may be adversely affected by other economic, business, and/or competitive factors; risks relating to the successful development of Revelation’s product candidates; the ability to successfully complete planned clinical studies of its product candidates; the risk that we may not fully enroll our clinical studies or enrollment will take longer than expected; risks relating to the occurrence of adverse safety events and/or unexpected concerns that may arise from data or analysis from our clinical studies; changes in applicable laws or regulations; expected initiation of the clinical studies, the timing of clinical data; the outcome of the clinical data, including whether the results of such study is positive or whether it can be replicated; the outcome of data collected, including whether the results of such data and/or correlation can be replicated; the timing, costs, conduct and outcome of our other clinical studies; the anticipated treatment of future clinical data by the FDA, the EMA or other regulatory authorities, including whether such data will be sufficient for approval; the success of future development activities for its product candidates; potential indications for which product candidates may be developed; the ability of Revelation to maintain the listing of its securities on NASDAQ; the expected duration over which Revelation’s balances will fund its operations; and other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the SEC by Revelation.

Company Contacts

Mike Porter
Investor Relations
Porter LaVay & Rose Inc.
Email: mike@plrinvest.com

Chester Zygmont, III
Chief Financial Officer
Revelation Biosciences Inc.
Email: czygmont@revbiosciences.com

SOURCE: Revelation Biosciences, Inc.

View the original press release on ACCESS Newswire

NEW YORK, NY / ACCESS Newswire / September 11, 2025 / Recycling was supposed to be the easy win for sustainability. Policymakers set bold targets, global brands pledged billions, and NGOs pressed for accountability. Yet despite all that ambition, the results speak for themselves. Recycling rates remain stuck, plastics continue to pile up, and skepticism runs deep across the supply chain.

That gap between ambition and outcome is exactly what SMX (NASDAQ:SMX) and Singapore’s A*STAR are solving with the world’s first national plastics passport. By embedding proof at the molecular level, their system is designed to fix the very flaws that have undermined recycling for decades.

At the root of recycling’s failure is not intent but structure. The frameworks built decades ago were designed too narrowly, audited too loosely, and fragmented by geography. The outcome was inevitable.

Fragmentation came first. Each country, and often each city, created its own patchwork of rules and collection standards. What qualifies as recycled content in one jurisdiction might not in another. The result is a global marketplace where no one can agree on what is credible, making it impossible for multinational brands to prove consistent compliance.

Inconsistent auditing followed. Most systems rely on paperwork, certifications, or periodic inspections. These are subjective, easy to manipulate, and incapable of providing continuous proof. When a brand says its packaging contains 30% recycled content, regulators and consumers have little more than a trust-me statement to rely on. That lack of transparency undermines confidence in the entire loop.

The final flaw is scope. Recycling frameworks built around PET bottles and food-grade rPET were always destined to disappoint. PET accounts for only a fraction of global plastic use. The real volume sits in industrial polymers, automotive resins, electronics, textiles, and construction-grade plastics. By leaving those categories outside the system, recycling was guaranteed to remain an aspiration rather than a reality.

Taken together, these three flaws are not minor oversights. They are the fatal design features that explain why decades of effort have not produced the results policymakers and brands promised.

The Passport That Rebuilds the System

SMX enters the story not as another recycling company, but as the architect of a system designed to work. Its molecular-level marking technology, which creates a digital plastic passport for all types of plastics, fixes the very flaws that have kept recycling from becoming functional.

Instead of fragmenting, the plastics passport unifies. By embedding a molecular marker directly into materials, not applied after the fact, SMX creates a digital, in Singapore’s case, national plastics passport, that can be scanned and trusted across borders. What makes these plastics passports so compelling is that, whether in Singapore, Europe, or the United States, the same verification and proof standards hold true. The fractured marketplace finally has a consistent standard. And the company’s Plastic Cycle Token (PCT) adds financial incentives.

Instead of paper audits, the passport delivers proof. A polymer carrying an SMX marker can be tracked at every step of its lifecycle, from production through use to recycling and reuse. This continuous verification replaces subjective claims with objective evidence. Brands and regulators do not need to wait for quarterly disclosures or rely on audits that only sample small windows in time. Proof is present in the material itself.

All types. Instead of focusing nearly exclusively on PET or rPET, the SMX plastics passport expands coverage. SMX’s markers work across all polymer types, from high-performance plastics in electronics to resins used in construction and automotive industries. That expansion changes the math entirely. Recycling can finally address the full plastics economy rather than a sliver of it.

By the way, it is no coincidence that Singapore has become the first country to implement this vision on a national scale. They have led in other markets, structurally changing some in the financial sector. By working with A*STAR and SMX to launch a plastics passport program, Singapore is leading again, this time transforming the idea of recycling from patchwork experiments into national infrastructure. That leadership is already influencing ASEAN, where the region can see a tangible pathway to replicate Singapore’s framework into a market worth more than S$4.2 billion annually.

Why the Fix Matters Now

Those billions are the tip of the sustainability iceberg, making the stakes for getting this right never higher. Governments are under pressure to prove their environmental policies create a measurable impact. Brands are under pressure from consumers and investors to back up sustainability claims with real evidence. Financial markets are searching for companies that can turn compliance into value creation.

With SMX, plastics recycling shifts from aspiration to infrastructure. Waste becomes verified feedstock, compliance becomes a source of defensible value, and sustainability becomes measurable. For governments, this means accountability that functions across borders. For brands, it means proof that holds up to scrutiny. For stakeholders, it signals a company not simply aligned with a trend but positioned to own the architecture of a new system.

The fatal flaw in recycling was never ambition. It was design. Now, with an SMX plastics passport program built at the molecular level, the design itself has been fixed. Plastics recycling finally has the chance to work as promised, and SMX is the company making that historic correction possible.

References

1. National Environment Agency (NEA). Waste & Recycling Statistics 2014 – 2023. Singapore: NEA; 2024.

2. Shunpoly.com. “How Much Plastic Is Wasted Each Year in Singapore?” Accessed 5 August 2025.

3. National Environment Agency (NEA). Waste-Statistics & Overall Recycling (interactive dashboard). Updated 2024; accessed 5 August 2025.

4. National Environment Agency (NEA). Mandatory Packaging Reporting portal. Accessed 5 August 2025.

5. Singapore Statutes Online. Environmental Public Health (Public Cleansing) Regulations – Incineration gate-fee schedule; revised 2024.

6. National Environment Agency (NEA). “New Licensing Regime for General Waste Disposal Facilities.” Technical brief & dialogue-session slides; 2024.

7. Nasdaq.com. “SMX Announces Planned Launch of World’s First Plastic Cycle Token.” Press release; 2024.

8. Yahoo! Finance. “SMX Plastic Cycle Token Is a Functional Market-Driven Solution…” News article; 2024.

9. Los Angeles Tribune. “Carbon Credits Had Their Day… Now the SMX Plastic Cycle Token…” Feature article; 2025.

10. National Environment Agency (NEA). Refuse Collection Fees for Households. Revised 2024; accessed 5 August 2025.

About SMX

As global businesses face new and complex challenges relating to carbon neutrality and meeting new governmental and regional regulations and standards, SMX is able to offer players along the value chain access to its marking, tracking, measuring and digital platform technology to transition more successfully to a low-carbon economy.

Forward-Looking Statements

The information in this press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “forecast,” “intends,” “may,” “will,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements in this press release may include, for example: matters relating to the Company’s fight against abusive and possibly illegal trading tactics against the Company’s stock; successful launch and implementation of SMX’s joint projects with manufacturers and other supply chain participants of gold, steel, rubber and other materials; changes in SMX’s strategy, future operations, financial position, estimated revenues and losses, projected costs, prospects and plans; SMX’s ability to develop and launch new products and services, including its planned Plastic Cycle Token; SMX’s ability to successfully and efficiently integrate future expansion plans and opportunities; SMX’s ability to grow its business in a cost-effective manner; SMX’s product development timeline and estimated research and development costs; the implementation, market acceptance and success of SMX’s business model; developments and projections relating to SMX’s competitors and industry; and SMX’s approach and goals with respect to technology. These forward-looking statements are based on information available as of the date of this press release, and current expectations, forecasts and assumptions, and involve a number of judgments, risks and uncertainties. Accordingly, forward-looking statements should not be relied upon as representing views as of any subsequent date, and no obligation is undertaken to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. As a result of a number of known and unknown risks and uncertainties, actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include: the ability to maintain the listing of the Company’s shares on Nasdaq; changes in applicable laws or regulations; any lingering effects of the COVID-19 pandemic on SMX’s business; the ability to implement business plans, forecasts, and other expectations, and identify and realize additional opportunities; the risk of downturns and the possibility of rapid change in the highly competitive industry in which SMX operates; the risk that SMX and its current and future collaborators are unable to successfully develop and commercialize SMX’s products or services, or experience significant delays in doing so; the risk that the Company may never achieve or sustain profitability; the risk that the Company will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the risk that the Company experiences difficulties in managing its growth and expanding operations; the risk that third-party suppliers and manufacturers are not able to fully and timely meet their obligations; the risk that SMX is unable to secure or protect its intellectual property; the possibility that SMX may be adversely affected by other economic, business, and/or competitive factors; and other risks and uncertainties described in SMX’s filings from time to time with the Securities and Exchange Commission.

EMAIL: info@securitymattersltd.com

SOURCE: SMX (Security Matters) Public Limited

View the original press release on ACCESS Newswire

Icotrokinra is a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor ¹

Filing based on four Phase 3 studies that met all primary and co-primary endpoints. This unprecedented data package includes head-to-head superiority comparisons versus deucravacitinib, adolescent data, and evaluation of difficult to treat skin sites^2,3,4,5,6

Submission underscores that icotrokinra has the potential to offer moderate-to-severe plaque psoriasis patients the combination of complete skin clearance and a favourable safety profile, relative to comparators, with the simplicity of a once-daily tablet. ^2,3,4,5,6

NEWARK, CA / ACCESS Newswire / September 11, 2025 / Protagonist Therapeutics, Inc. (“Protagonist” or the “Company”) today announced the submission of an application to the European Medicines Agency (EMA) by Johnson & Johnson seeking the first approval of icotrokinra, a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor for the treatment of adults and pediatric patients 12 years of age and older (adolescents) with moderate-to-severe plaque psoriasis (PsO).¹Icotrokinra is an investigational targeted oral tablet that is designed to block the IL-23 receptor,which underpins the inflammatory response in PsO and offers potential in other IL-23-mediated diseases.^7,8

The application included data from four Phase 3 studies conducted as part of the ICONIC clinical development program, including ICONIC-LEAD^a, ICONIC-TOTAL^b, and ICONIC-ADVANCE 1 & ICONIC-ADVANCE 2^c. Treatment with icotrokinra met all primary and co-primary endpoints across the development program among adults and adolescents 12 years of age and older with moderate-to-severe PsO, demonstrating significant skin clearance and a favourable safety profile in a once-daily tablet, as previously established in the ICONIC-LEAD and ICONIC-TOTAL clinical studies. ^2,3,4,5,6 Results from the ICONIC-ADVANCE 1 & 2 studies show icotrokinra achieved co-primary endpoints and showed superiority to deucravacitinib in moderate-to-severe PsO.^d,e,5,6 Across all studies, pooled safety data showed a similar proportion of patients experienced adverse events (AEs) between icotrokinra (49.1%) and placebo (51.9%) groups, with no new safety signals identified to date.^2,3,4,5,6

“This EMA submission comes on the heels of a U.S. FDA NDA filing in late July, both of which are supported by a very comprehensive clinical data package demonstrating the significant impact icotrokinra has in the clinical setting, and highlighting its potential to disrupt the current treatment paradigm and transform the approach of plaque psoriasis care,” said Dinesh V. Patel, Ph.D., President and Chief Executive Officer at Protagonist. “We look forward to sharing additional data in ongoing studies, including the ANTHEM ulcerative colitis 12-week data at the upcoming United European Gastroenterology meeting as well as data from the ICONIC-LEAD and ICONIC-ADVANCE trials being presented at the European Academy of Dermatology and Venereology Congress in Paris next week.”

Data submitted to the EMA as part of the application include:

• Results from the Phase 3 ICONIC-LEAD study, presented as a late-breaking abstract at the 2025 American Academy of Dermatology (AAD) Annual Meeting, showed that icotrokinra successfully met the co-primary endpoints of an Investigator’s Global Assessment (IGA)^d score of 0/1 (clear or almost clear skin) and Psoriasis Area and Severity Index (PASI)^e 90 compared to placebo at Week 16.²

• A subgroup analysis of ICONIC-LEAD, presented at the 2025 World Congress of Pediatric Dermatology (WCPD), which demonstrated adolescents treated with once-daily icotrokinra achieved higher rates of clear or almost clear skin at Week 16 compared to patients receiving placebo, with no new safety signals identified.³

• Data from the Phase 3 ICONIC-TOTAL study, presented at the 2025 Society for Investigative Dermatology (SID) Annual Meeting, that highlighted the potential of icotrokinra in patients with difficult-to-treat scalp and genital psoriasis.⁴

• Results from the Phase 3 ICONIC-ADVANCE 1 & ICONIC-ADVANCE 2 studies, that further reinforced the overall efficacy profile, met co-primary endpoints of IGA 0/1 and PASI 90 versus placebo at Week 16. Icotrokinra also met all key secondary endpoints at Weeks 16 and 24 that measured superiority to deucravacitinib in patients with moderate-to-severe PsO.^5,6,9

• Long-term data from the ICONIC development program, including at least 52-weeks of treatment for ICONIC-LEAD and ICONIC-TOTAL, and results from a randomized withdrawal analysis evaluating the durability of response, are being prepared for presentation at a future medical meeting.

Editor’s notes:

1. ICONIC-LEAD is a Phase 3 randomized controlled trial (RCT) evaluating the efficacy and safety of icotrokinra compared with placebo in 684 participants (icotrokinra=456; placebo=228) 12 years of age or older with moderate-to-severe plaque psoriasis, measuring the percentage of participants who achieve a PASI 90 response and an IGA score of 0/1 with at least a 2-grade improvement as co-primary endpoints. ICONIC-LEAD enrolled 66 adolescent patients.¹⁰

2. ICONIC-TOTAL is a Phase 3 RCT evaluating the efficacy and safety of icotrokinra compared with placebo for the treatment of plaque psoriasis in 311 participants (icotrokinra=208; placebo=103) with at least moderate severity affecting special areas (e.g., scalp, genital and/or hands and feet) with overall IGA score of 0 or 1 with at least a 2-grade improvement as the primary endpoint.¹¹

3. ICONIC-ADVANCE 1 & 2 are Phase 3 RCTs evaluating the efficacy and safety of icotrokinra compared with placebo and deucravacitinib in participants with moderate-to-severe plaque psoriasis with PASI 90 and IGA score of 0/1 with at least a 2-grade improvement as co-primary endpoints.^9,12

4. The IGA is a five-point scale with a severity score ranging from 0 to 4, where 0 indicates clear, 1 is minimal, 2 is mild, 3 is moderate and 4 indicates severe disease.¹³

5. The PASI score grades the amount of surface area on each body region that is covered by psoriasis plaques and the severity of plaques for their redness, thickness and scaliness.¹⁴ PASI 90 corresponds to an improvement of >=90% in PASI score from baseline.¹⁴

About the ICONIC Clinical Development Programme
The pivotal Phase 3 ICONIC clinical development program of icotrokinra (JNJ-2113) in adult and adolescent individuals with moderate-to-severe plaque psoriasis was initiated with two studies in Q4 2023 – ICONIC-LEAD and ICONIC-TOTAL – pursuant to the license and collaboration agreement between Protagonist Therapeutics, Inc. and Janssen Biotech, Inc., a Johnson & Johson company.¹⁵

ICONIC-LEAD (NCT06095115) is a RCT to evaluate the efficacy and safety of icotrokinra compared with placebo in participants with moderate-to-severe plaque psoriasis, with PASI 90 and IGA score of 0 or 1 with at least a 2-grade improvement as co-primary endpoints.¹⁰

ICONIC-TOTAL (NCT06095102) is a RCT to evaluate the efficacy and safety of icotrokinra compared with placebo for the treatment of psoriasis in participants with at least moderate severity affecting special areas (e.g., scalp, genital, and/or hands and feet) with an overall IGA score of 0 or 1 with at least a 2-grade improvement as the primary endpoint.¹¹

Other Phase 3 studies in the development programme include ICONIC-ADVANCE 1 (NCT06143878) and ICONIC-ADVANCE 2 (NCT06220604), which are evaluating the efficacy and safety of icotrokinra compared with both placebo and deucravacitinib in adults with moderate-to-severe plaque psoriasis.^9,12

ICONIC-ASCEND will evaluate the efficacy and safety of icotrokinra compared with placebo and ustekinumab in participants with moderate-to-severe plaque psoriasis. ICONIC-PsA 1 (NCT06878404) and ICONIC-PsA 2 (NCT06807424) will evaluate the efficacy and safety of icotrokinra compared to placebo in participants with active psoriatic arthritis. ^16,17

About Plaque Psoriasis
Plaque psoriasis (PsO) is a chronic immune-mediated disease resulting in overproduction of skin cells, which causes inflamed, scaly plaques that may be itchy or painful. It is estimated that 8 million Americans and more than 125 million people worldwide live with the disease. Nearly one-quarter of all people with plaque PsO have cases that are considered moderate to severe. On Caucasian skin, plaques typically appear as raised, red patches covered with a silvery white buildup of dead skin cells or scale. On skin of color, the plaques may appear darker and thicker, and more of a purple, gray, or dark brown color. Plaques can appear anywhere on the body, although they most often appear on the scalp, knees, elbows, and torso. Living with plaque PsO can be a challenge and impact life beyond a person’s physical health, including emotional health, relationships, and handling the stressors of life. Psoriasis on highly visible areas of the body or sensitive skin, such as the scalp, hands, feet, and genitals, can have an increased negative impact on quality of life.

About Icotrokinra (JNJ-77242113, JNJ-2113)
Investigational icotrokinra is the first targeted oral peptide designed to selectively block the IL-23 receptor, which underpins the inflammatory response in moderate-to-severe plaque PsO, ulcerative colitis, and offers potential in other IL-23-mediated diseases. Icotrokinra binds to the IL-23 receptor with single-digit picomolar affinity and demonstrates potent, selective inhibition of IL-23 signaling in human T cells. The license and collaboration agreement established between Protagonist Therapeutics, Inc. and Janssen Biotech, Inc., a Johnson & Johnson company, in 2017 enabled the companies to work together to discover and develop next-generation compounds that ultimately led to icotrokinra.

Icotrokinra was jointly discovered and is being developed pursuant to the license and collaboration agreement between Protagonist and Johnson & Johnson. Johnson & Johnson retains exclusive worldwide rights to develop icotrokinra in Phase 2 clinical trials and beyond, and to commercialize compounds derived from the research conducted pursuant to the agreement against a broad range of indications.

Icotrokinra is being studied in the pivotal Phase 3 ICONIC clinical development program in moderate-to-severe plaque psoriasis and active psoriatic arthritis and the Phase 2b ANTHEM-UC study in moderately to severely active ulcerative colitis.

About Protagonist

Protagonist Therapeutics is a discovery through late-stage development biopharmaceutical company. Two novel peptides derived from Protagonist’s proprietary discovery platform are currently in advanced Phase 3 clinical development, with New Drug Application (NDA) for icotrokinra submitted to the FDA in July and in the NDA submission for rusfertide expected by end of 2025. Icotrokinra (formerly, JNJ-2113), is a first-in-class investigational targeted oral peptide that selectively blocks the Interleukin-23 receptor (“IL-23R”) which is licensed to Janssen Biotech, Inc., a Johnson & Johnson company. Following icotrokinra’s joint discovery by Protagonist and Johnson & Johnson scientists pursuant to the companies’ IL-23R collaboration, Protagonist was primarily responsible for development of icotrokinra through Phase 1, with Johnson & Johnson assuming responsibility for development in Phase 2 and beyond. Rusfertide, a mimetic of the natural hormone hepcidin, is currently in Phase 3 development for the rare blood disorder polycythemia vera (PV). Rusfertide is being co-developed and will be co-commercialized with Takeda Pharmaceuticals pursuant to a worldwide collaboration and license agreement entered in 2024 under which the Company remains primarily responsible for development through NDA filing. The Company also has a number of pre-clinical stage drug discovery programs addressing clinically and commercially validated targets, including IL-17 oral peptide antagonist PN-881, obesity triple agonist peptide PN-477, and the oral hepcidin program.

More information on Protagonist, its pipeline drug candidates and clinical studies can be found on the Company’s website at https://www.protagonist-inc.com/.

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding the potential benefits of icotrokinra, and expectations regarding the icotrokinra development program. In some cases, you can identify these statements by forward-looking words such as “anticipate,” “believe,” “may,” “will,” “expect,” or the negative or plural of these words or similar expressions. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, our ability to develop and commercialize our product candidates, our ability to earn milestone payments under our collaboration agreements with Janssen and Takeda, our ability to use and expand our programs to build a pipeline of product candidates, our ability to obtain and maintain regulatory approval of our product candidates, our ability to operate in a competitive industry and compete successfully against competitors that have greater resources than we do, and our ability to obtain and adequately protect intellectual property rights for our product candidates. Additional information concerning these and other risk factors affecting our business can be found in our periodic filings with the Securities and Exchange Commission, including under the heading “Risk Factors” contained in our most recently filed periodic reports on Form 10-K and Form 10-Q filed with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release.

Investor Relations Contact

Corey Davis, Ph.D.
LifeSci Advisors
+1 212 915 2577
cdavis@lifesciadvisors.com

Media Contact

Virginia Amann, Founder/CEO
+1 833 500 0061 ext 1
ENTENTE Network of Companies
virginiaamann@ententeinc.com

¹ Bissonnette R, et al. Data presentation. A phase 2, randomized, placebo-controlled, dose-ranging study of oral JNJ-77242113 for the treatment of moderate-to-severe plaque psoriasis: FRONTIER 1. Presented at WCD 2023, July 3-8.

² Bissonnette, R et al. Icotrokinra, a Targeted Oral Peptide That Selectively Blocks the Interleukin-23-Receptor, for the Treatment of Moderate-to-Severe Plaque Psoriasis: Results Through Week 24 of the Phase 3, Randomized, Double-blind, Placebo-Controlled ICONIC-LEAD Trial. Late-breaking research presentation (Abstract #66708) at the American Academy of Dermatology (AAD) 2024 Annual Meeting. Accessed July 2025.

³ Eichenfield, L et al. Efficacy and Safety of Icotrokinra, a Novel Targeted Oral Peptide (IL-23R-inhibitor), in Adolescents With Moderate-to- Severe Plaque Psoriasis: Subgroup Analyses From a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study (ICONIC-LEAD). Presented at the World Congress of Pediatric Dermatology (Abstract #0054). Accessed July 2025.

⁴ Gooderham, M.J. et al. Phase 3 results from an innovative trial design of treating plaque psoriasis involving difficult-to-treat, high-impact sites with icotrokinra, a targeted oral peptide that selectively inhibits the IL-23-receptor. Presented at the 2025 Society for Investigative Dermatology (Abstract #LB1142). Accessed July 2025.

⁵ Data on file (RF-454780). JNJ-77242113 Topline Results: Study 77242113PSO3002. Accessed July 2025.

⁶ Data on file (RF-454781). JNJ-77242113 Topline Results: Study JNJ77242113PSO3004. Accessed July 2025.

⁷ Razawy W, et al. The role of IL‐23 receptor signaling in inflammation‐mediated erosive autoimmune arthritis and bone remodeling. Eur J Immunol. 2018 Feb; 48(2): 220-229.

⁸ Tang C, et al. Interleukin-23: as a drug target for autoimmune inflammatory diseases. Immunology. 2012 Feb; 135(2): 112-124.

⁹ Clinicaltrials.gov. A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2). Identifier NCT06220604. https://clinicaltrials.gov/study/NCT06220604. Accessed July 2025.

¹⁰ Clinicaltrials.gov. A study of JNJ-2113 in adolescent and adult participants with moderate-to-severe plaque psoriasis (ICONIC-LEAD). Identifier NCT06095115. https://classic.clinicaltrials.gov/ct2/show/NCT06095115. Accessed July 2025.

¹¹ Clinicaltrials.gov. A study of JNJ-2113 for the treatment of participants with plaque psoriasis involving special areas (scalp, genital, and/or palms of the hands and the soles of the feet) (ICONIC-TOTAL). Identifier NCT06095102.

¹² Clinicaltrials.gov. A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis. Identifier NCT06143878. https://clinicaltrials.gov/study/NCT06143878?term=jnj-77242113&rank=10. Accessed July 2025.

¹³ Simpson E, Bissonnette R, Eichenfield LF, et al. The validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD™): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis [published online April 25, 2020]. J Am Acad Dermatol. doi: 10.1016/j.jaad.2020.04.104. Accessed July 2025.

¹⁴ Thompson Jr, D. How the Psoriasis Area and Severity Index works. Everyday Health. Available at: https://www.everydayhealth.com/psoriasis/living-with/how-the-pasi-index-works. Accessed July 2025.

¹⁵ Protagonist Therapeutics. Press release. Protagonist announces advancement of JNJ-2113 across multiple indications. Available at: https://www.accesswire.com/791174/protagonist-announces-advancement-of-jnj-2113-across-multiple-indications. Accessed July 2025.

¹⁶ Clinicaltrials.gov. A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis (ICONIC-PsA 1). Identifier NCT06878404. https://clinicaltrials.gov/study/NCT06878404

¹⁷ A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced Participants With Active Psoriatic Arthritis (ICONIC-PsA 2). Identifier NCT06807424. https://clinicaltrials.gov/study/NCT06807424

SOURCE: Protagonist Therapeutics

View the original press release on ACCESS Newswire

HOUSTON, TX / ACCESS Newswire / September 11, 2025 / EON Resources Inc. (NYSE American:EONR) (“EON” or the “Company”) is an independent upstream energy company with 20,000 leasehold acres in the Permian Basin. The fields have a total of 750 producing and injection wells producing over 1,000 barrels of oil per day. Today, the Company announced the entering into a Farmout Agreement (the “Farmout”) with a subsidiary of Virtus Energy Partners, LLC (“Virtus”) on September 9, 2025.

Under the Farmout, Virtus acquired the right to develop the Company’s San Andres formation within the Grayburg Jackson Field (“GJF”) where it believes as many as 90 horizontal drilling locations are prospective. Virtus will be the designated operator and lead the development efforts.

The Frisco, Texas based Virtus team has a recent and relevant history as the preeminent horizontal San Andres developer in the Permian Basin. Organically and through acquisitions, Virtus created immense value in the state line area of Texas and New Mexico; growing from zero to more than thirty thousand gross operated barrels of oil equivalent per day from more than two hundred horizontal San Andres wells. Virtus’ management team gained their expertise developing conventional and unconventional reservoirs with modern technology in most of the notable United States basins before settling on their strategy of redeveloping conventional oilfields in the Permian Basin of Texas and New Mexico.

The closing of the drilling program farmout was simultaneous with the closing of the funding for the settlement of seller obligations and the retirement of senior debt. For additional information regarding the funding, the related press release is available on the EON press releases page of our website.

Highlights of the program and farmout agreement:

• Virtus paid EON $5.0 million for the acquisition of a 65% working interest in the leasehold rights in the San Andres formation. The Company retains a 35% non-operated working interest in the San Andres and 100% operated working interest in the remaining productive formations.

• As many as 90 horizontal wells are expected to be drilled at a cost between $3.5 million and $4.0 million per well. Cumulative capital investment by Virtus and EON is expected to exceed $300 million over the life of the project.

• The annual drilling program is expected to range from 10 to 20 new horizontal wells per year with initial production rates of 300 to 500 barrels of oil per day (“BOPD”).

• Over the life of the drilling program, gross oil production is expected to exceed 20,000 BOPD with 35%, or 7,000 BOPD, net to the Company’s working interest.

• The first three wells are anticipated to be completed by mid-year 2026.The costs associated with the first three wells are solely Virtus’ responsibility.

• The Economic Summary Projection of the anticipated development plan (the “Projection”) prepared by Virtus estimates more than ninety-five million dollars of reserve value based on net present value discounted at ten percent (“NPV-10”) net to EON’s retained ownership interest. The Projection estimates the reserves attributable to EON’s interest may exceed ten million barrels of oil and six billion cubic feet of natural gas.

“As we scouted the Permian Basin for our next project, Virtus was pleased to find the Grayburg Jackson Field,” said Lance Taylor, Chief Executive Officer of Virtus. “The subsurface characteristics are very similar to, and in many ways, better than, our incredibly successful horizontal San Andres efforts along the Texas and New Mexico state line. We have great expectations for this new venture and are thrilled to be partnering with EON’s team and our new sponsor.”

“We are very pleased to team with Virtus whose team has a proven track record. We have always been confident in the potential of the application of horizontal drilling technology to San Andres formation across our leasehold, but wanted to partner with a proven technical team. It will be a pleasure to work with the Virtus staff, who are very experienced and professional,” said Dante Caravaggio, President and CEO of EON. “An additional benefit to EON and our shareholders is the net proceeds from the first 3 wells are expected to cover about half of the drilling capital needs for the next wave of horizontal drilling. We expect that once 10 horizontal wells are drilled and producing that the future drilling capex becomes self-sustaining.”

About EON Resources Inc.

EON is an independent upstream energy company focused on maximizing total returns to its shareholders through the development of onshore oil and natural gas properties in a diversified portfolio of long-life producing oil and natural gas properties and other energy holdings. EON’s approach is to build an energy company through acquisition and through selective development of its properties. Class A Common Stock of EON trades on the NYSE American Stock Exchange under the symbol of “EONR” and the Company’s public warrants trade under the symbol of “EONRWS”. For more information on the Company, please visit the EON website.

About the Grayburg-Jackson Field Property

Our Grayburg-Jackson Field (“GJF”) is primarily a waterflood property located on the Northwest Shelf of the Permian Basin in Eddy County, New Mexico. The GJF comprises of 13,700 contiguous leasehold acres with 342 producing wells, 207 injection wells and 1 water source well for a total of 550 wells. Leasehold rights include the Seven Rivers, Queen, Grayburg and San Andres intervals that range from as shallow as 1,500 feet to 4,000 feet in depth. The December 2024 reserve report from our third-party engineer, Haas and Cobb Petroleum Consultants, LLC, estimates proven reserves of approximately 14.0 million barrels of oil and 2.8 billion cubic feet of natural gas. The mapped original-oil-in-place (“OOIP”) is approximately 956 million barrels of oil. Primary production is currently from the Seven Rivers formation. In addition to proven reserves, the Company believes it may access an additional 34 million barrels of oil by adding perforations in the Grayburg and San Andres formations, plus another 40 million barrels from a horizontal drilling program in the San Andres. More information on the property can be located on the Grayburg-Jackson Field page of our website.

About the South Justis Field Property

The South Justis Field (“SJF”) is a carbonate reservoir similar to the rest of the Permian, and is located in Lea County, New Mexico approximately 100 miles from the GJF. The SJF is comprised of 5,360 contiguous acres containing 208 total producing and injection wells with well spacing of 50 acres. The producing formations include the Glorietta, Blinebry, Tubb, Drinkard and Fusselman intervals that range from 5,000 feet to 7,000 feet in depth. The original-oil-in-place (“OOIP”) is approximately 207 million barrels of oil. More information on the property can be located on the South Justis Field page of our website.

Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties that could cause actual results to differ materially from what is expected. Words such as “expects,” “believes,” “anticipates,” “intends,” “estimates,” “seeks,” “may,” “might,” “plan,” “possible,” “should” and variations and similar words and expressions are intended to identify such forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Such forward-looking statements relate to future events or future results, based on currently available information and reflect the Company’s management’s current beliefs. A number of factors could cause actual events or results to differ materially from the events and results discussed in the forward-looking statements. Important factors – including the availability of funds, the results of financing efforts and the risks relating to our business – that could cause actual results to differ materially from the Company’s expectations are disclosed in the Company’s documents filed from time to time on EDGAR (see www.edgar-online.com) and with the Securities and Exchange Commission (see www.sec.gov). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Except as expressly required by applicable securities law, the Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Investor Relations
Michael J. Porter, President
PORTER, LEVAY & ROSE, INC.
mike@plrinvest.com

SOURCE: EON Resources Inc.

View the original press release on ACCESS Newswire

UK cyber compliance is changing, and native MS tools alone won’t protect you from the threats and the regulators!

LONDON, GB / ACCESS Newswire / September 11, 2025 / CyberSentriq, a unified cybersecurity and data resilience platform purpose-built for MSPs, warns that the UK’s upcoming Cyber Security and Resilience Bill  will demand a rethink among Managed Service Providers (MSPs). With the UK Parliament set to grant regulators more teeth, MSPs will face tougher expectations not just around best practice, but mandatory compliance. The Bill is anticipated to reach Parliament in the second half of 2025, although the exact timeline remains uncertain. 

One thing is clear: relying solely on native Microsoft 365 security features will not be good enough.

Despite what the E5 license price tag might suggest, Microsoft’s native tools – Exchange Online Protection, Defender for Office 365 and Purview – leave dangerous blind spots such as gaps in detection and response, configuration complexity and inconsistency and the risk of single-vendor reliance.

The government knows it, threat actors know it, and if MSPs don’t get ahead of it, their clients will soon find out the hard way.

James Griffin, CEO at CyberSentriq, a unified cybersecurity and data resilience platform purpose-built for MSPs, warns that relying solely on Microsoft 365 for security leaves MSPs exposed to growing threats like BEC attacks, phishing and QR code scams. With the UK’s Cyber Security and Resilience Bill set to raise the bar on compliance and reporting, MSPs must move beyond native tools and adopt a layered security strategy to demonstrate true operational resilience.

The Reality of Shared Responsibility

Microsoft operates under a shared responsibility model, meaning they keep the cloud infrastructure running, but the responsibility for protecting the data is on the customer. Or, in the case of most UK SMBs, on the MSP they work with.

This is where the cracks can start to show. Exchange Online Protection misses low-volume Business Email Compromise (BEC) attacks. Defender isn’t tuned for QR code phishing or MFA bypasses. Audit logs? They’re either buried in Purview or missing altogether on lower-tier plans.

We all know that the threat of a breach is real and growing. Indeed, our own recent research confirms this and paints quite a stark picture:

• 64% of organisations expected phishing threats to increase in 2025.

• 1 in 5 MSP customers suffered a successful BEC attack in 2024.

• 45% of MSP customers experienced a breach of sensitive employee data.

• Over 20% were hit by credential theft via QR code phishing, an attack vector that bypassed Microsoft 365’s native defences entirely.

Take the increasing use of generative AI and deepfake-based impersonation attacks into account, and the potential risk grows exponentially. These aren’t theoretical threats; they’re happening now – and the regulators are watching.

Microsoft 365 isn’t the enemy, but on its own, it’s not enough

I’m not calling for you to abandon Microsoft and its native security tools, but there needs to be a sense of realism. Microsoft 365 is a powerful productivity suite, but it’s not a fully-fledged cybersecurity platform. In fact, 98% of the organisations sampled in our research using Microsoft 365 said that third-party security solutions are “highly important” for defending against advanced threats.

Perhaps this is why MSPs are shifting to layered protection strategies such as:

• AI-powered email filtering and behavioural detection

• DNS-level filtering and link rewriting

• Proactive phishing simulation and user training

• Backup and rapid recovery across email, endpoints and SaaS apps

This isn’t security overkill; it’s the modern-day baseline.

Get ahead of the regulation or risk being left behind

The upcoming Cyber Security and Resilience Bill aims to drive up standards and is expected to introduce stricter incident reporting obligations, resilience testing and penalties for non-compliance.

Smart MSPs are taking the opportunity to reassess their tech stack. This isn’t only for the sake of compliance, but also because the reputational and financial damage from a breach is too great to risk. MSPs must demonstrate not only uptime, but also proactive cyber resilience – the ability to detect, defend, respond and recover at speed.

The Bottom Line

If you’re an MSP relying solely on Microsoft 365 to keep clients safe, you’re not just under-protected – you’re underprepared. The cybersecurity landscape has changed, the law is catching up, and it’s time your security strategy changed too.

About CyberSentriq:
CyberSentriq is an integrated cybersecurity and data protection platform, leveraging solutions from two best-of-breed vendors in the MSP space. Partnering with over 3,000 MSPs and protecting over 150,000 SMBs globally, CyberSentriq provides an unmatched combination of proactive AI-driven email and web security, advanced data protection, and operational resilience.

The CyberSentriq platform offers:

• AI-driven threat intelligence and detection

• Advanced email security at both the Mail Exchange (MX) and Integrated Cloud Email Security (ICES) layers.

• Cloud-based data backup and recovery

• Security awareness services

• Email archiving and encryption.

For more information, visit www.CyberSentriq.com

SOURCE: CyberSentriq

Related Images

View the original press release on ACCESS Newswire

SASKATOON, SK / ACCESS Newswire / September 11, 2025 / Yip Hong’s Dim Sum Restaurant has been recognised with the 2025 Consumer Choice Award in the Chinese Restaurants category for Saskatoon. This recognition reflects more than two decades of serving the community with authentic Chinese cuisine and an unparalleled dim sum experience.

Since opening its doors in 2004, Yip Hong’s has become a staple in Saskatoon’s dining scene. Known for its spacious and welcoming environment, the restaurant offers guests a peaceful, family-friendly setting to enjoy traditional Chinese dishes.

“Our goal has always been to bring people together through food,” says the Yip Hong’s Dim Sum Restaurant team. “Receiving the Consumer Choice Award shows us that our commitment to authenticity and quality continues to resonate with the community.”

Saskatoon’s Destination for Dim Sum

Yip Hong’s is best known for offering Saskatoon’s most extensive and authentic dim sum selection. From steamed dumplings and buns to savoury rolls and traditional favourites, every dish is crafted with care to capture the essence of Chinese culinary tradition. The menu also includes a wide variety of classic Chinese dishes, ensuring there is something to delight every palate.

Recognition Rooted in Community Trust

The Consumer Choice Award is the only organisation in North America that recognises business excellence based entirely on the opinions of consumers. Winners are chosen through independent research that evaluates reputation, customer satisfaction, and overall business excellence.

For Yip Hong’s, this award is a reflection of the loyalty and support of Saskatoon diners who have made the restaurant a trusted destination for gatherings, celebrations, and memorable meals.

Continuing A Tradition of Excellence

As Yip Hong’s Dim Sum Restaurant celebrates its recognition with the 2025 Consumer Choice Award, the team remains dedicated to blending time-honoured flavours with modern convenience. Whether it is a family meal, a special celebration, or a casual outing, Yip Hong’s continues to offer Saskatoon an unforgettable dining experience.

To explore the menu or plan your next visit, go to www.yiphongsdimsum.com.

About Yip Hong’s Dim Sum Restaurant
Founded in 2004, Yip Hong’s Dim Sum Restaurant has been serving authentic Chinese cuisine to the Saskatoon community for more than 20 years. With a spacious, family-friendly atmosphere and a wide menu featuring both traditional dim sum and classic Chinese dishes, Yip Hong’s has become a trusted name in local dining. Learn more at www.yiphongsdimsum.com.

About Consumer Choice Award
Since 1987, Consumer Choice Award has been recognising and promoting business excellence across North America. Through a rigorous selection process, only the most outstanding businesses in each category earn this prestigious recognition. Learn more at www.ccaward.com.

Contact Information
Sumi Saleh
Communications Manager
ssaleh@ccaward.com

SOURCE: Consumer Choice Award

View the original press release on ACCESS Newswire

New Dalet intelligent interface simplifies even the most complex production and media supply chain operations, enabling users to streamline workflows through a familiar, natural language user experience.

NEW YORK, NY / ACCESS Newswire / September 11, 2025 / Dalet today announced a transformative leap forward for media operations: Agentic Artificial Intelligence (AI) that unifies the Dalet ecosystem under one natural language conversational‑style user experience. Far more than an AI chatbot, Dalia is an intelligent layer embedded across Dalet Flex, Dalet Pyramid, Dalet InStream, Dalet Brio, and Dalet Amberfin, featuring a family of media-aware agents that act as assistants to facilitate complex workflows across ingest, production, rights management, distribution and archive. By combining the simple-to-use characteristics of SaaS point solutions with the enterprise strength of Dalet’s architecture and workflow expertise, the company has made a game-changing move forward, giving customers both the industry’s most powerful news, sports, and media supply chain solution and its most user‑friendly.

“After a year of shaping and executing our product strategy, we’re thrilled to bring this vision to life,” said Stephen Garland, Chief Product and Technology Officer at Dalet. “From day one, we have challenged ourselves and the industry to deliver the kind of seamless, user‑centric experience that consumers now expect. What we’re unveiling isn’t just another tool or AI chatbot. It’s intelligence beyond an agent, a transformational leap that unifies the entire Dalet ecosystem under a single interface. With this launch, media professionals can reimagine how they work, leveraging the full power of our platform through a conversation with a trusted assistant.”

Read about Dalet’s product strategy and journey in Stephen’s article: Breaking the Bottleneck: Building Time to Value Solutions.

Built on Dalet’s open core API, the agentic interface sits above all applications in the Dalet portfolio, offering a single conversational entry point to powerful functions. Users can ask the agent to locate assets, build title collections based on rights status, trigger review workflows, or schedule live ingest, and the system will execute these tasks end‑to‑end.

Unlike generic chatbots, Dalet’s conversational AI interface and Agents are “media aware”: trained on the company’s own orchestration and media engine, not on customer data. This allows users to securely interact with a full range of media types directly within the chat. Training and analyzing of media is done within the core platform, providing complete control of what engines access customers’ content. Dalet AI Agents understand how to search, clip, transcode, and package content without users leaving the chat. This approach augments traditional user interfaces for many day‑to‑day tasks, giving users the ability to perform complex operations with ease.

Inside Dalet’s Innovative In-House Start-Up
The new Agentic AI capability is the result of Dalet’s bold approach to innovation, driven by Dalet CPTO, Stephen Garland. Building on his proven track record of scaling innovation across other industries, Stephen defined and executed a strategy for media that combines the rigor of an enterprise roadmap with the agility of a startup. To accelerate this vision, he established a “startup within Dalet”. The cross-functional team was led by Erwan Kerfourn, together with Matteo De Martinis and Aaron Kroger.

“This started as a ‘Skunk Works’ inside Dalet, a startup-style lab where a cross-functional team could move at breakneck speed,” said Erwan Kerfourn. “By combining that freedom to experiment with Dalet’s agile architecture, we turned bold ideas into a market-ready breakthrough. The result is an intelligent layer that feels like a media-savvy colleague, eliminating friction from workflows and giving customers new freedom to create, sell, distribute, and publish faster than ever.”

Operating at a rapid pace, while remaining aligned with Dalet’s overall strategy, the team could experiment, iterate, and bring breakthrough ideas to market without disrupting daily operations.

Experience Dalia at IBC2025 – Hall 7, Stand A43
Attendees are invited to schedule a meeting with the Dalia team to explore how Dalet’s latest innovation can help organizations unlock greater operational efficiencies and new business opportunities.

Book a meeting now: www.dalet.com/events/ibc

About Dalet

Dalet empowers media-rich organizations to transform their production and distribution workflows – accelerating media operations, maximizing collaboration and creating higher value from content. As a leading media technology and service provider with over three decades of innovation, our software solutions enable greater control, enhanced visibility and increased productivity for content professionals and storytellers around the globe. Leading organizations such as Fox Networks Group, Arsenal Football Club, MediaCorp, and the BBC trust Dalet to support their daily content operations. Our team is driven by a passion for media and committed to empowering a world where compelling stories are beautifully made, effortlessly told and thoughtfully delivered. Learn more at www.dalet.com.

Press Contact

Melissa Harding
Grithaus Agency
(e) melissa@grithaus.agency
(p) +44 7594 079738

SOURCE: Dalet

View the original press release on ACCESS Newswire

CALGARY, AB / ACCESS Newswire / September 11, 2025 / Consumer Choice Award is proud to recognize GreenFox Windows & Doors as the 2025 winner in the Windows and Doors category for Southern Alberta. This honour celebrates the company’s commitment to product excellence, innovative technology, and dependable service for homeowners in Calgary and beyond.

Known for providing some of the most thermally efficient windows on the market, GreenFox Windows & Doors helps homeowners reduce energy bills and increase comfort year-round-despite Alberta’s harsh climate conditions. With certified Window Wise installers, lifetime transferable warranties on products, and a 25-year workmanship warranty, GreenFox ensures every project delivers long-lasting value and peace of mind.

“We’re proud to receive the Consumer Choice Award for 2025. This recognition is a testament to the trust our customers place in us and our team’s dedication to delivering industry-leading solutions and service,” said the team at GreenFox Windows & Doors. “From our very first consultation to final installation, we work to exceed expectations every step of the way.”

GreenFox offers an expansive selection of products and services, including:

• Energy-efficient vinyl and aluminum-clad windows

• Entry, patio, and storm doors

• Custom installations tailored to the unique needs of every home

• Expert service backed by comprehensive warranties

Every GreenFox product is built with durability and design in mind. Whether it’s enhancing curb appeal, improving energy efficiency, or increasing overall home value, GreenFox Windows & Doors has become a trusted partner for residential and commercial clients alike across Alberta.

Backed by a team of highly trained professionals and a customer-first approach, GreenFox has earned its reputation as a leader in the industry. From their exceptional in-home consultations to professional installations, the company remains focused on providing quality, reliability, and innovation.

The Consumer Choice Award is based on an independent, statistically supported research process to determine the top-ranked businesses in each region. GreenFox Windows & Doors’ continued recognition in Southern Alberta reaffirms its role as a go-to provider for premium window and door solutions.

To learn more about GreenFox Windows & Doors or book a consultation, CLICK HERE or visit www.greenfoxwindows.ca.

About Consumer Choice Award:
Consumer Choice Award has been recognizing and promoting business excellence in North America since 1987. Its rigorous selection process ensures that only the most outstanding service providers in each category earn this prestigious recognition. Visit www.ccaward.com to learn more.

Contact Information
Sumi Saleh
Communications Manager
ssaleh@ccaward.com

SOURCE: Consumer Choice Award

View the original press release on ACCESS Newswire